TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00043121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT02803372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed circulatory management
Description: In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine circulatory management
Description: Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
Study: NCT00623012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
Study: NCT04018170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study drug
Description: oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
Study: NCT02355912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered knee and ankle prosthesis
Description: A powered knee and ankle prosthesis developed by Vanderbilt University.
Study: NCT02751307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 500 mg
Description: metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 500 mg
Description: metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin 500 mg
Description: metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine 100 mg
Description: Clozapine dose remained unchanged during metformin intervention period in recruited patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine 100 mg
Description: Clozapine dose remained unchanged during metformin intervention period in recruited patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clozapine 100 mg
Description: Clozapine dose remained unchanged during metformin intervention period in recruited patients.
Study: NCT03463265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus, single agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus + temozolomide
Description: temozolomide, combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus + bevacizumab
Description: bevacizumab, combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus + lomustine
Description: lomustine, combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus + marizomib (MRZ)
Description: marizomib (MRZ), combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus + temozolomide + radiotherapy
Description: temozolomide + radiotherapy, combination
Study: NCT00685178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial
Study: NCT00043121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02616432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Description: Three-dimensional imaging of both breasts in standard CC and MLO views
Study: NCT03231020

Intervention type: OTHER
Intervention: Interview
Description: The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period.

Intervention type: OTHER
Intervention: Interview
Description: The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (\< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period.
Study: NCT01076894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intercostal anesthesia
Description: In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
Study: NCT02545231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 1mg
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 4mg
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Study: NCT00366340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
Study: NCT01242397

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT pacing
Description: The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT pacing
Description: The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
Study: NCT00685178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Reinforcement
Description: monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
Study: NCT02959619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Oral ensartinib was given daily at escalating doses in a 28-day cycle
Study: NCT01846091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IT
Study: NCT01756716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low
Description: MT-3995 Low dose for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Description: MT-3995 High dose for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weeks
Study: NCT04345640

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00854126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Escalating repeating dose
Study: NCT00364559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg 10 days daily
Study: NCT03531827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: enzalutamide is an androgen receptor (AR) antagonist that is standard care therapy for metastatic prostate cancer
Study: NCT04541693

Intervention type: DEVICE
Group type: OTHER
Intervention: Full revision
Description: Both cup and stem require revision

Intervention type: DEVICE
Group type: OTHER
Intervention: Cup revision
Description: Only the cup requires revision
Study: NCT00685178

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Reinforcement
Description: monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + NonCR
Description: participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
Study: NCT01907412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations Coparenting Program
Description: Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff.
Study: NCT06157775

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear-wave elastography
Description: Shear-wave elastography using a manual ultrasound with a 9L-Probe in B-mode.
Study: NCT04600401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentis Plus+ (Experimental Group)
Description: Each factor can be considered a module, so it is a modular program. So, each module has 3 sessions to be carried out in full. It is a systematic program, so the order of the sessions is regulated by the letters A, B and C for each module. The modules to be worked on correspond to the low-level or languising factors identified after the application of the positive mental health questionnaire (PMHQ). After the application of the PMHQ, people are grouped with the same module to work.
Study: NCT02668432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
Study: NCT02107443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment Summary
Description: Complete summary of results from the Geriatric Assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment Targeted Recommendations
Description: Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment (GA)
Description: A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Assessment (GA)
Description: A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
Study: NCT01766583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292 + lenalidomide
Description: CC-292 + lenalidomide
Study: NCT03753880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOPATCH Sealing Hemostat
Description: Hemopatch sealing hemostat used after LR to cover the resection surface
Study: NCT02234310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Adjustments to the dose and interval of rFIXFc was made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There was an option to start study dosing as episodic treatment (on-demand).
Study: NCT01739387

Intervention type: DEVICE
Intervention: Flutiform® pMDI and Breath Actuated Inhaler (BAI)
Description: Both devices contain placebo

Intervention type: DEVICE
Intervention: Flutiform® pMDI and Breath Actuated Inhaler (BAI)
Description: Both devices contain placebo
Study: NCT00946647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Panobinostat was supplied by Novartis as immediate-release hard gelatin capsules in strengths of 5 mg, 10 mg, and 20 mg packaged in high density polyethylene bottles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Azacytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Study: NCT03724461

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity resistance training (12 weeks)
Description: High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity resistance training (12 weeks)
Description: High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light-moderate intensity resistance training (12 weeks)
Description: Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light-moderate intensity resistance training (12 weeks)
Description: Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (12 weeks)
Description: No resistance training during the intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (12 weeks)
Description: No resistance training during the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One High Intensity resistance training session
Description: High intensity resistance training, 1 training session
Study: NCT02229149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving.
Study: NCT03724461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Light-moderate intensity resistance training session
Description: Light-moderate intensity resistance training, 1 training session
Study: NCT04769882

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG Laser
Description: Selected Er:YAG settings: enamel removal program for adult, with normal modality (frequency: 20 Hz, energy: 400 mJ, power: 8.0 W, air: 80%, water: 60%) and dentin removal program for adult, with normal modality (frequency: 20 Hz, energy: 200 mJ, power: 4.0 W, air: 90%, water: 30%)
Study: NCT00650078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR prednisone
Description: 1 x 5 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1x daily
Study: NCT02175160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking and functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking and functionality
Study: NCT04283045

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.